Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs ANHYDRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,Hypertension (off-label use)
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Partially metabolized by the liver; primarily excreted unchanged in urine.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
95% bound, primarily to albumin.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Oral: ~65% (range 50-80%) due to first-pass metabolism.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
GFR 10-50 m L/min: 50 mg every 12 hours. GFR <10 m L/min: 50 mg every 24 hours or not recommended.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): avoid use.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
1-2 mg/kg/dose once daily; maximum 100 mg/day.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Start at 12.5-25 mg once daily; titrate slowly due to risk of hypotension and electrolyte imbalance.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
No FDA black box warning.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Electrolyte imbalance (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypotension,Ototoxicity (especially with rapid IV administration or renal impairment),Hyperuricemia and gout,Sulfonamide cross-sensitivity in sulfa-allergic patients
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Anuria,Severe renal failure,Hepatic coma or pre-coma,Severe electrolyte depletion,Hypersensitivity to sulfonamides
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) as hyperkalemia may occur. Limit salt substitutes containing potassium. Grapefruit juice may increase drug absorption; avoid concurrent use. Alcohol may enhance orthostatic hypotension.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been associated with an increased risk of congenital anomalies in some studies, including cleft lip/palate and cardiac defects. Second and third trimesters: can cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and possibly intrauterine growth restriction. Crosses the placenta. Use only if clearly needed for maternal conditions like hypertension or edema.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Cyclothiazide is excreted into human breast milk. The milk-to-plasma ratio is not well defined for cyclothiazide but for thiazides generally is around 0.5-1.0. May suppress lactation. Potential for infant adverse effects (e.g., electrolyte disturbances, thrombocytopenia). Use caution in breastfeeding; alternatives are preferred.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal blood flow, and GFR) may reduce effectiveness of thiazides. No specific dosing adjustment guidelines for cyclothiazide; however, if used, start at lowest effective dose and titrate based on response. Typical adult dose: 2 mg once daily; may adjust to 1-4 mg. Monitor for hypotension and electrolyte imbalances. Avoid in preeclampsia due to decreased placental perfusion.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
ANHYDRON (cyclothiazide) is a thiazide-like diuretic used for hypertension and edema. Monitor serum potassium and glucose levels; hypokalemia and hyperglycemia are common. Use with caution in renal impairment (Cr Cl <30 m L/min). Avoid in patients with anuria or sulfonamide allergy.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Do not stop abruptly without consulting your doctor; gradual dose reduction may be needed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs ANHYDRON, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. ANHYDRON is a Thiazide Diuretic that works by Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and ANHYDRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of ANHYDRON is: Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and ANHYDRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. ANHYDRON is classified as Category C. Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been asso. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.